Sign In
Buy MOH
$184.82
+4.75 (+2.64%)
At Close: Jun 03, 2026
Masimo's (MASI) Q4 Earnings Surpass Estimates, Margins Up
03:06pm, Wednesday, 16'th Feb 2022 Zacks Investment Research
Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q4 sales.
PacBio's (PACB) Q4 Earnings Miss Estimates, Revenues Top
02:53pm, Wednesday, 16'th Feb 2022 Zacks Investment Research
PacBio (PACB) sees strength in Q4 segmental revenues, led by robust consumable and instrument sales.
Mednax (MD) Pursues $1.1B Transactions to Reduce Debt Burden
02:48pm, Wednesday, 16'th Feb 2022 Zacks Investment Research
Mednax (MD) issues senior notes, and a new revolving credit facility coupled with a term loan remains in place, which is aimed at reducing MD's debt level and associated interest expenses.
Is Aptinyx Inc. (APTX) Outperforming Other Medical Stocks This Year?
02:40pm, Wednesday, 16'th Feb 2022 Zacks Investment Research
Here is how Aptinyx Inc. (APTX) and Molina (MOH) have performed compared to their sector so far this year.
Humana (HUM) to Support Eligible Medicaid Members in Louisiana
08:05pm, Tuesday, 15'th Feb 2022 Zacks Investment Research
Humana (HUM) is picked by the Louisiana Department of Health for a contract win to help serve the Medicaid members in Louisiana.
Ecolab (ECL) Q4 Earnings & Revenues Beat Mark, Margins Down
05:08pm, Tuesday, 15'th Feb 2022 Zacks Investment Research
Ecolab's (ECL) robust performance across most of its segments drives its Q4 sales despite business challenges.
Centene (CNC) Boosts Presence in Louisiana With Contract Win
05:05pm, Tuesday, 15'th Feb 2022 Zacks Investment Research
Centene's (CNC) latest contract renewal tends to improve health outcomes of Medicaid members of Louisiana.
Henry Schein (HSIC) Q4 Earnings Top Estimates, Margins Grow
02:53pm, Tuesday, 15'th Feb 2022 Zacks Investment Research
Robust performances by all three operating businesses drove Henry Schein's (HSIC) Q4 revenues.
Omnicell (OMCL) Q4 Earnings Miss Estimates, Revenues Beat
02:48pm, Tuesday, 15'th Feb 2022 Zacks Investment Research
Robust performance by the Product and Service segments is driving Omnicell's (OMCL) fourth-quarter top line.
Molina Healthcare, Inc. (MOH) CEO Joe Zubretsky on Q4 2021 Results - Earnings Call Transcript
08:35pm, Thursday, 10'th Feb 2022 Seeking Alpha
Molina Healthcare (MOH) Q4 Earnings Beat on Higher Premiums
05:05pm, Thursday, 10'th Feb 2022 Zacks Investment Research
Molina Healthcare (MOH) expects its 2022 business to witness reduced impacts from COVID. Strong Medicare and Medicaid performance is set to buoy results.
Molina Healthcare, Inc. (MOH) CEO Joe Zubretsky on Q4 2021 Results - Earnings Call Transcript
03:35pm, Thursday, 10'th Feb 2022
Molina Healthcare, Inc. (MOH) CEO Joe Zubretsky on Q4 2021 Results - Earnings Call Transcript
Molina Healthcare (MOH) Q4 Earnings Beat on Higher Premiums
01:50pm, Thursday, 10'th Feb 2022
Molina Healthcare (MOH) expects its 2022 business to witness reduced impacts from COVID. Strong Medicare and Medicaid performance is set to buoy results.
Molina (MOH) Q4 Earnings and Revenues Top Estimates
10:55pm, Wednesday, 09'th Feb 2022 Zacks Investment Research
Molina (MOH) delivered earnings and revenue surprises of 2.13% and 3.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Molina Healthcare Non-GAAP EPS of $2.88 beats by $0.12, revenue of $7.41B beats by $220M
09:25pm, Wednesday, 09'th Feb 2022 Seeking Alpha
Molina Healthcare press release (MOH): Q4 Non-GAAP EPS of $2.88 beats by $0.12.Revenue of $7.41B (+41.4% Y/Y) beats by $220M.The Company issued its full year 2022 earnings guidance…
